Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
The latest update is out from PDS Biotechnology ( (PDSB) ).
PDS Biotechnology Corporation’s board of directors has scheduled the company’s 2026 Annual Meeting of Stockholders for August 10, 2026, with further details to be provided in a definitive proxy statement filed with the SEC. Because this meeting date falls more than 30 days after the anniversary of the 2025 annual meeting, the company set June 25, 2026, as the deadline for shareholders to submit proposals for inclusion in the 2026 proxy materials under SEC Rule 14a-8, reinforcing the timetable and procedural framework for investor participation in corporate governance.
The most recent analyst rating on (PDSB) stock is a Buy
with a $15.00 price target.
To see the full list of analyst forecasts on PDS Biotechnology stock,
see the PDSB Stock Forecast page.
Spark’s Take on PDSB Stock
According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral.
The score is held down primarily by very weak financial performance (pre-revenue, sustained losses, cash burn, and balance-sheet risk). Offsetting this, the latest earnings call and recent updates point to meaningful clinical/protocol progress and improved expense trends, while technicals are neutral and valuation offers limited support due to negative earnings and no dividend.
To see Spark’s full report on PDSB stock,
click here.
More about PDS Biotechnology
PDS Biotechnology Corporation operates in the biotechnology sector, focusing on the research and development of immunotherapy-based treatments. The company targets areas of high unmet medical need, positioning itself within the broader biopharmaceutical and life sciences market.
Average Trading Volume: 1,021,476
Technical Sentiment Signal: Sell
Current Market Cap: $58.61M
For detailed information about PDSB stock, go to TipRanks’ Stock Analysis page.